AMRS - Amyris, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.2600
-0.5200 (-18.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.7800
Open2.8000
Bid2.2600 x 2200
Ask2.3600 x 800
Day's Range2.2300 - 2.8000
52 Week Range2.1700 - 9.2900
Volume6,227,791
Avg. Volume2,976,539
Market Cap172.949M
Beta (3Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-3.5220
Earnings DateMay 13, 2019 - May 17, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • 3 Takeaways From Amyris' Q4 2018 Earnings Report
    Motley Fool12 hours ago

    3 Takeaways From Amyris' Q4 2018 Earnings Report

    The company reported poor operating performance in 2018, but has attempted to focus the attention of investors on its future.

  • GlobeNewswireyesterday

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Amyris, Inc. Investors (AMRS)

    Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ: AMRS) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On this news, Amyris’ share price fell $0.78, or nearly 20% to close at $3.10 per share on March 20, 2019, thereby injuring investors.

  • Business Wire2 days ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Amyris, Inc. Investors (AMRS)

    Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ: AMRS) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On this news, Amyris’ share price fell $0.78, or nearly 20% to close at $3.10 per share on March 20, 2019, thereby injuring investors.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of AMRS earnings conference call or presentation 18-Mar-19 8:30pm GMT

    Q4 2018 Amyris Inc Earnings Call

  • Business Wire3 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Amyris, Inc. Investors (AMRS)

    Law Offices of Howard G. Smith announces an investigation on behalf of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ: AMRS) investors concerning the Company and its officers’ possible violations of federal securities laws. On this news, Amyris’ share price fell $0.78, or nearly 20% to close at $3.10 per share on March 20, 2019, thereby injuring investors.

  • Here's Why Amyris Collapsed Today
    Motley Fool3 days ago

    Here's Why Amyris Collapsed Today

    The company notified the Securities and Exchange Commission that it couldn't file its annual report on time. It gave three reasons.

  • Benzinga4 days ago

    Amyris Signs $300M Deal For Fermentation-Derived CBD Products

    Amyris, which produces ingredients in the health and wellness, clean beauty and flavors and fragrances markets, said it has clinched a deal with newly formed LAVVAN Inc., which is working on bringing the first fermentation-derived cannabinoid products to market. The announcement comes after a previously announced term sheet and includes further milestone payments related to additional targeted products. Amyris, with its expertise in terpenes, said it will leverage its automated processes and R&D staff in the development of cannabinoid pathways.

  • Amyris Inc (AMRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Amyris Inc (AMRS) Q4 2018 Earnings Conference Call Transcript

    AMRS earnings call for the period ending December 31, 2018.

  • GlobeNewswire5 days ago

    Amyris Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Announces Signing of $300 Million Definitive Cannabinoid Agreement

    EMERYVILLE, Calif., March 18, 2019 -- Q4 2018 GAAP revenue of $19.4 million, compared with GAAP revenue of $80.6 million (reflected $57.3 million during period for agreement.

  • GlobeNewswire5 days ago

    Amyris Finalizes Cannabinoid Development, Licensing and Commercialization Agreement Containing $300 Million of R&D and Milestone Payments and a Long-Term Royalty Stream

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has signed a final definitive agreement for cannabinoid development, licensing and commercialization containing $300 million of R&D and milestone payments plus long-term royalties. The agreement between Amyris and LAVVAN, Inc., a newly-formed company backed by leaders across the pharmaceutical, cannabis, and financial sectors, intends to bring the first fermentation-derived cannabinoid products to market. Today’s announcement follows the previously announced binding term sheet and includes further milestone payments related to additional targeted products.

  • GlobeNewswire12 days ago

    Amyris to Present at 31st Annual Roth Conference on Tuesday, March 19, 2019

    Amyris will provide an update on its business during the presentation, which is scheduled for Tuesday, March 19, at 12:30 p.m. ET. A live webcast of the presentation including slides and a replay will be available on the investor relations section of the company’s website at http://investors.amyris.com. Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.

  • Analysts Estimate Amyris (AMRS) to Report a Decline in Earnings: What to Look Out for
    Zacks13 days ago

    Analysts Estimate Amyris (AMRS) to Report a Decline in Earnings: What to Look Out for

    Amyris (AMRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did You Manage To Avoid Amyris’s (NASDAQ:AMRS) Devastating 93% Share Price Drop?
    Simply Wall St.13 days ago

    Did You Manage To Avoid Amyris’s (NASDAQ:AMRS) Devastating 93% Share Price Drop?

    Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held Amyris, Inc. (NASDAQ:AMRS) for five years would be nursing their metaphorical wounds since theRead More...

  • A Massive Disruption Could Be on the Way for Marijuana: 3 Stocks Poised to Profit
    Motley Fool13 days ago

    A Massive Disruption Could Be on the Way for Marijuana: 3 Stocks Poised to Profit

    Cannabinoids that don't require cannabis just might make these stocks huge winners in the future.

  • GlobeNewswire19 days ago

    Amyris to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Monday, March 18, 2019

    EMERYVILLE, Calif., March 05, 2019 -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the fourth quarter and fiscal year ended December 31, 2018 after market close.

  • Will Cannabis Producers Ditch Greenhouses for Bioreactors?
    Motley Fool22 days ago

    Will Cannabis Producers Ditch Greenhouses for Bioreactors?

    Plants aren't always the perfect medium for producing high-value compounds. Turns out, cannabinoids can be brewed with microbes instead.

  • ACCESSWIRElast month

    Signals Point To A Resurgence In Gold That Could Rival The Cannabis Renaissance

    As recession fears emerge amid slowing global growth, signals are emerging of a possible resurgence in gold, precious metals, and the mining industry as a whole. The public mining sector has been stagnant (for investors) for most of the 10-year U.S. economic boom, but that could be changing. Gold has finally found a bid, and M&A among major industry players is booming as they scoop up under-appreciated assets.

  • GlobeNewswirelast month

    Amyris Is Selected by NIH Grant Recipient, IDRI, to Engineer Molecules for Vaccine Adjuvant Applications

    Amyris, Inc. (AMRS), and IDRI (Infectious Disease Research Institute), are pleased to announce IDRI’s receipt of a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (part of the U.S. National Institutes of Health) to discover sustainable alternatives to shark squalene to use as vaccine adjuvants (grant number: R01AI135673). IDRI has selected Amyris and the University of Nottingham, (UK) as partners because of their record of success in engineering pure molecules from sustainable sources at low cost.

  • GlobeNewswirelast month

    Amyris Appoints Industry Veteran as President, Sweeteners and Ingredients, to Deliver Accelerated Growth

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced the appointment of Oreste Fieschi as President of Sweeteners & Ingredients, to lead the commercial growth of its sweetener business and the implementation of its strategy to build capability across the entire ingredients portfolio. Oreste has a successful track record in commercial leadership roles in the food and beverage and natural ingredients sectors, along with deep expertise in global markets.  This new position is driven by growth across Amyris’s businesses and within the expanding market for the company’s new, sugarcane-derived zero calorie sweetener.

  • ACCESSWIRElast month

    These 4 Marijuana Stocks Could Be Positioned For A Big Month

    CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / The marijuana stock market, as many have come to recognize, has existed for a short period of time relative to other more established markets. Due to this fact, there have been quite a bit of volatility surrounding companies in the cannabis industry. As we continue to move through the month of February, the hope is that the cannabis industry will recognize even more gains in the future.

  • InvestorPlacelast month

    Amyris Stock Can Run Much Higher Than You Think

    Investors can now consider renewable products company Amyris (NASDAQ:AMRS) as a "marijuana stock." The Emeryville, California-based firm signed a deal to license cannabinoid products. This sent AMRS stock surging much higher in Tuesday trading.Now, investors must decide if and how to trade Amyris stock. Given the renewed popularity of marijuana stocks, the stock will likely remain a momentum stock for the foreseeable future. New Deal Changes the Perception of AMRS StockAMRS stock rose by more than 73% on Tuesday upon announcing its entrance in the cannabinoid market. The company did not reveal the name of its partner in this agreement; however, we know the value of the deal will come to $255 million. Some of this could come in the form of royalty payments as Amyris works to bring sustainably sourced CBD to the beverage and skin care markets. The final agreement should happen by the end of March. Products from this deal should appear on shelves 18 to 24 months after final approval.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBefore this agreement, Amyris survived as a little-known industrial biotech company that launched its IPO in 2010. Since peaking in 2011, the stock has lost about 99% of its value. Now, thanks to cannabis, it could be on its way to a long-awaited comeback. The Deal Will Bolster Robust Revenue GrowthWhile the association with weed will likely boost AMRS stock, its financials have shown improvement for some time. In the middle of the decade, stagnant revenue and massive losses seem to define AMRS. * 7 Recession-Proof Stocks to Buy as the Boom Ends However, the company more than doubled revenues in 2016 and again in 2017. Although this growth has slowed, analysts had predicted revenue increases would remain well into the double digits before this announcement. Losses have also narrowed in recent years. With cannabis-related sales coming in, both revenue and earnings should improve dramatically.Also, even after its massive upward surge, AMRS trades at just over two times sales. This compares well to cannabis industry giants such as Canopy Growth (NYSE:CGC) and Tilray (NASDAQ:TLRY), both of which maintain triple-digit price-to-sales ratios.Furthermore, Canopy's market cap of nearly $16 billion is more than 40 times the size of Amyris's $390 million market cap. Yet with 2018 revenues of only C$255 million ($193.4 million), Canopy will only bring in about 20% more in revenue than the $161.8 million analysts expect from Amyris. While I do not think AMRS will catch up to Canopy's market cap, I think this deal will help close much of that gap. AMRS Could Benefit From an American Cannabis BoomMoreover, marijuana stock investors remember the Canadian cannabis boom that cooled off following full legalization. Now, with hemp achieving legal status in the U.S., a comparable American cannabis boom looks to have just begun. Canopy, who will begin producing hemp in New York, again trades at levels not seen since legal status became official in Canada. * 10 F-Rated Stocks That Could Break Your Portfolio If such a boom has in fact started in the U.S., this should bode well for AMRS stock regardless of fundamentals. Given the 73% surge in one day, the stock will more likely pull back for now. However, over time, the boom in cannabis stocks should take it higher. This separation from fundamentals will turn off some buyers. However, for those comfortable trading mostly on momentum, I see the potential for profit in Amyris stock. Final Thoughts on Amyris StockThe move into the cannabis sector will boost Amyris stock in the near term regardless of earnings. Amyris has spent years as a little-known biotech company whose stock had gained little traction in recent years. However, a move into the marijuana sector sent AMRS more than 70% higher in just one day.This occurs as a U.S. cannabis boom has likely ignited thanks to hemp's new legal status. Despite losses, AMRS stock looks cheap in comparison to marijuana giants such as Canopy Growth. If nothing else, the momentum should take the company's price-to-sales ratio much higher.Like other marijuana stocks, AMRS should grow well beyond its fundamentals. This will mean any movement or purchase decisions will drive on momentum shifts. This goes beyond the comfort level of some investors. However, for those willing to take that risk, AMRS appears poised to bring higher returns to those with a high tolerance for risk.As of this writing, Will Healy did not hold a position in any of the aforementioned securities. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Won Super Bowl Sunday * 7 High-Yield ETFs for Brave Investors * 10 F-Rated Stocks That Could Break Your Portfolio Compare Brokers The post Amyris Stock Can Run Much Higher Than You Think appeared first on InvestorPlace.

  • What Is Amyris (AMRS), And Why Is Its Stock Soaring?
    Zacks2 months ago

    What Is Amyris (AMRS), And Why Is Its Stock Soaring?

    Shares of bioscience firm Amyris (AMRS) skyrocketed more than 70% on Tuesday after the company announced a collaboration deal focused on developing, licensing, and commercializing cannabinoid products.

  • ACCESSWIRE2 months ago

    These Marijuana Stocks Should Be On Your Radar

    Although society has progressed much further in terms of recognizing the potential benefits of cannabis, there are still individuals who have yet to come to terms with the fact that more people are supportive of legalization. As a result of the recent passing of laws like the US Farm Bill, as well as Canada's country-wide legalization, individuals who would otherwise scoff at the cannabis industry, have now been brought into the fold due to the excitement surrounding the industry. Nabis Holdings (INNPF) (NAB), Amyris Inc (AMRS), InMed Pharmaceuticals Inc (IMLFF) (IN.TO), and Pyxus International Inc (PYX) are four cannabis companies working towards improving the quality of life for their consumers.

  • Option Bulls Flock to Penny Stock After Weed Deal
    Schaeffer's Investment Research2 months ago

    Option Bulls Flock to Penny Stock After Weed Deal

    Amyris disclosed a cannabinoid partnership